盐酸帕罗西汀
中文名称 | 盐酸帕罗西汀 |
---|---|
中文同义词 | D4-盐酸帕罗西汀;半水帕罗西汀;(-)-反式-4R-(4-氟苯基)-3S-{[3',4'-(亚甲二氧基)苯氧基]甲基}-哌啶盐酸盐半水合物;盐酸帕罗西汀半水合物;(-)-(3S,4R)-PAROXETINE HYDROCHLORIDE HEMIHYDRATE;(办证)盐酸帕罗西汀PAROXETINE HYDROCHLORIDE HEMIHYDRAT;盐酸帕罗西汀半水合物, 选择性5-羟色胺重吸收抑制剂 (SSRI);(3S,4R)-3-((苯并[D][1,3]DIOXOL-5-氧基)甲基)-4-(4-氟苯基)哌啶盐酸盐半水合物 |
英文名称 | PAROXETINE-D4 HCL |
英文同义词 | Piperidine, 3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-, hydrochloride, hydrate (2:1), (3S,4R)- (9CI);Paroxetine Hydrochloride (350 mg);Paroxetine Hydrochloride (350 mg)G0D0030.972mg/mg(ai);PAROXETINE-D4 HCL;PAROXETINE HYDROCHLORIDE 1/2H2O;Piperidine,3-[(1,3-benzodioxol-5-yloxy)Methyl]-4-(4-fluorophenyl)-, hydrochloride, hydrate(2:2:1), (3S,4R)-;Paroxetine hydrochloride (3S-trans)-3-[(1,3-Benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine hydrochloride;Paroxetine hydrochloride hemihydrate, >=99% |
CAS号 | 110429-35-1 |
分子式 | C19H23ClFNO4 |
分子量 | 383.84 |
EINECS号 | 000-000-0 |
相关类别 | 神经信号;对照品;化工中间体;原料药;医用原料;Active Pharmaceutical Ingredients;Cnbio;Serotonin;医药原料;化学试剂;化工产品 |
Mol文件 | 110429-35-1.mol |
结构式 | ![]() |
盐酸帕罗西汀 性质
熔点 | 121-131 C |
---|---|
储存条件 | under inert gas (nitrogen or Argon) at 2-8°C |
溶解度 | 微溶于水,易溶于甲醇,微溶于乙醇(96%)和二氯甲烷。 |
形态 | 粉末 |
颜色 | 白色 |
最大波长(λmax) | 292nm(H2O)(lit.) |
Merck | 14,7043 |
CAS 数据库 | 110429-35-1 |
IC50: 14 μM (GRK2)
Paroxetine (1 μM and 10 μM) distinctly restrains T cell migration induced by CX3CL1 through inhibiting GRK2. Paroxetine inhibits GRK2 induced activation of ERK. Paroxetine (10 μM) reduces pro-inflammatory cytokines in LPS-stimulated BV2 cells. Paroxetine (0-5 μM) leads to a dose-dependent inhibition on LPS-induced production of TNF-α and IL-1β in BV2 cells. Paroxetine also inhibits lipopolysaccharide (LPS)-induced nitric oxide (NO) production and inducible nitric oxide synthase (iNOS) expression in BV2 cells. Paroxetine (5 μM) blocks LPS-induced JNK activation and attenuates baseline ERK1/2 activity in BV2 cells. Paroxetine relieves microglia-mediated neurotoxicity, and suppresses LPS-stimulated pro-inflammatory cytokines and NO in primary microglial cells.
Paroxetine treatment obviously attenuates the symptoms of CIA rats. Paroxetine treatment clearly prevents the histological damage of joints and alleviates T cells infiltration into synovial tissue. Paroxetine reveals a strong effect on inhibiting CX3CL1 production in synovial tissues. Paroxetine (20 mg/kg/day) reduces the myocyte cross-sectional area in rat and ROS formation in the remote myocardium. Paroxetine reduces the susceptibility to ventricular tachycardia. Paroxetine treatment following MI decreases LV remodeling and susceptibility to arrhythmias, probably by reducing ROS formation. In CCI paroxetine-treated group, paroxetine (10 mg/kg, i.p.) produces hyperalgesia at days 7 and 10 (P<0.01), but a decrease in pain behavior is seen at day 14. Moreover, paroxetine (10 mg/kg) significantly attenuates tactile hypersensitivity when compared to CCI vehicle-treated group.
安全信息
危险品标志 | F,C,Xn |
---|---|
危险类别码 | 11-34-36/37/38-22 |
安全说明 | 16-26-36/37/39-45-36 |
危险品运输编号 | UN 3077 9 / PGIII |
WGK Germany | 3 |
RTECS号 | TM4569320 |
危险等级 | IRRITANT |
海关编码 | 29349990 |
更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
---|---|---|---|---|---|
2024/08/19 | 46263 | 盐酸帕罗西汀半水合物 Paroxetine hydrochloride hemihydrate, 98% | 110429-35-1 | 1g | 602元 |
2024/08/19 | 46263 | 盐酸帕罗西汀半水合物 Paroxetine hydrochloride hemihydrate, 98% | 110429-35-1 | 5g | 2055元 |